SARS-CoV-2 RNA in plasma is associated with ICU admission and mortality in patients hospitalized with COVID-19

Christian Prebensen¹², Peder L Myhre²³, Christine Jonassen⁴, Anbjørg Rangberg⁴, Anita Blomfeldt⁵, My Svensson⁶, Torbjørn Omland²³, Jan-Erik Berdal¹²

¹ Department of Infectious Diseases, Division of Medicine, Akershus University Hospital, Lørenskog, Norway
² Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
³ Department of Cardiology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway
⁴ Center for Laboratory Medicine, Østfold Hospital Trust, Grålum, Norway
⁵ Department of Microbiology and Infection Control, Division for Diagnostics and Technology, Akershus University Hospital, Norway
⁶ Department of Research, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.

Corresponding author: Jan-Erik Berdal, MD, PhD, Department of Infectious Diseases, Akershus University Hospital, Sykehusveien 27, 1478 Lørenskog, Norway.
Tel: +47 48205817. E-mail: jan-erik.berdal@ahus.no
Abstract:

The clinical significance of SARS-CoV-2 RNA in the circulation is unknown. In this prospective cohort study, we detected viral RNA in the plasma of 58/123 (47%) patients hospitalized with COVID-19. RNA was detected more frequently, and levels were higher, in patients who were admitted to the ICU and/or died.

Keywords: SARS-CoV-2, COVID-19, RNAemia, viral load, antibodies
Introduction:

While infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) frequently causes severe pulmonary disease, autopsy studies suggest viral dissemination to multiple organs, including heart, kidney, brain and GI tract [1]. The clinical significance of detecting viral RNA outside the respiratory tract is unknown. In this prospective observational study, we aimed to quantify SARS-CoV-2 RNA in the plasma and upper respiratory tract of patients hospitalized with coronavirus disease 2019 (COVID-19) and evaluate the association between RNA loads, disease severity and the SARS-CoV-2-specific antibody response.

Methods:

The COronaVirus Disease MECHanisms study (COVID-MECH, NCT04314232) recruited consecutive adult patients admitted to Akershus University Hospital with COVID-19 confirmed by RT-PCR between March 18th and May 4th 2020. Written informed consent was granted by study participants, or by next-of-kin if the patient was unable to consent. The study was approved by local regulatory authorities.

The predefined primary endpoint was a composite of intensive care unit (ICU) admission >24 hours and in-hospital mortality. Clinical data were extracted from electronic patient records. Routine biochemistry was taken at admission and study-specific samples of EDTA plasma and serum were taken at three time points; baseline (enrollment), day 3 (±1 day) and day 9 (±2 days) in patients who were still hospitalized (details in Supplementary Figure 1).
SARS-CoV-2 RNA was detected in plasma samples and upper respiratory tract swabs by RT-PCR and RNA levels were estimated using the cycle threshold (Ct) value. In PCR-positive plasma samples, RNA was quantified and expressed as log10 copies/mL (details in Supplementary Methods File 1). Upper respiratory samples were combined oropharyngeal and nasopharyngeal swabs, taken in the emergency department unless the patient had a positive RT-PCR from another laboratory within the preceding week. All RT-PCRs were performed as described by Corman et al., targeting the viral envelope (E)-gene [2].

Total antibodies against SARS-CoV-2 nucleocapsid (NP) were quantified using the Elecsys Anti-SARS-CoV-2 test on the cobas e801 module (Roche, Penzberg, Germany). IgG antibodies directed against subunits S1 and S2 of the SARS-CoV-2 spike protein were quantified using the LIAISON SARS-CoV-2 S1/S2 IgG assay and the Liaison XL chemiluminescence analyzer (DiaSorin, Saluggia, Italy).

Data are presented as N (%), mean ± SD and median [Q1, Q3]. Differences between groups were assessed by t-tests, Mann-Whitney U tests, chi-square tests and Spearman tests, as appropriate. All statistical analyses were performed in Stata 16 (StataCorp, College Station, TX, USA). P-values <0.05 were considered statistically significant.

Results:

Plasma and serum samples were available from 123/135 (91%) patients, of whom 35 (28%) patients reached the primary endpoint. 31 patients were admitted to the ICU; 29 received mechanical ventilation and four died. Another four patients with do-not-intubate orders died on regular wards. All ICU admissions and deaths were attributable to COVID-19. Clinical, biochemical, virological and
serological data are presented in Table 1 (data on 12 patients without biobank samples in Supplementary Table 1).

SARS-CoV-2 RNAemia was detected in at least one sample in 58/123 (47%) patients, and in a significantly higher proportion of patients who were admitted to the ICU or died (80% vs. 34%, p<0.001). RNAemia was detected in 48/123 (39%) patients at baseline, a median 0 [-1, 3] days before ICU admission. 24 (41%) of patients with detectable RNAemia had Ct values >38, below the quantitation limit of 2.70 log_{10} copies/mL, and Ct values were therefore used in this analysis. Of note, the lowest Ct value of 25.9 (corresponding to an RNA load of 6.3 log_{10} copies/mL) was observed in a female ICU patient with a prolonged course of disease. RNAemia was significantly more frequent at all time points in patients who reached the primary endpoint, whereas RNA loads were significantly higher at baseline and day 3 (Table 1, Supplementary Figure 2A). In a logistic regression analysis where nine patients with baseline samples taken after ICU admission were excluded, baseline RNAemia and RNA load were both significantly associated with ICU admission and/or death (Supplementary Table 2). This association persisted after adjusting for age, sex and race (Model #1) and BMI, diabetes mellitus and symptom duration (Model #2). There was no correlation between days from symptom onset and RNAemia frequency or RNA load at baseline.

Ct values from diagnostic upper respiratory swabs taken at admission were available from 102 (83%) patients, including all 35 who were admitted to the ICU or died. There was no association between upper respiratory Ct values and the primary endpoint (Supplementary Figure 2B). There was no correlation between upper respiratory Ct values and RNAemia frequency or plasma RNA loads, nor with the number of days from symptom onset to admission.
Titers of anti-SARS-CoV-2 NP total Ig and anti-spike IgG both rose progressively in the majority of patients (Supplementary Figure 2C). There was no difference in the titers of total Ig or IgG at any timepoint between patients who reached the primary endpoint or not. There was no correlation between baseline RNAemia, RNA loads or upper respiratory Ct values and subsequent antibody titers. While four patients had low or undetectable antibody titers out to 20+ days after symptom onset, there was no association between a lack of an antibody response and the primary endpoint, baseline RNAemia and RNA loads, or admission upper respiratory Ct values.

**Discussion:**

In this prospective study of patients hospitalized with COVID-19 we detected SARS-CoV-2 RNAemia in 47% of included patients, and a significantly higher frequency of RNAemia and higher RNA loads in patients who required ICU admission and/or died. By contrast, RT-PCR Ct values in upper respiratory swabs obtained at admission yielded no prognostic information. The development of SARS-CoV-2-specific antibodies was independent of RNAemia, RNA loads in plasma, upper respiratory Ct values and the study primary endpoint.

To our knowledge, no prospective cohort studies of this size have detected circulating SARS-CoV-2 RNA in such a high proportion of patients with COVID-19. Our findings confirm and extend those of Hogan et al., who detected RNAemia in 28/85 (32.9%) hospitalized patients in a retrospective study, and similarly found that RNAemia was associated with ICU admission and hospital mortality [3]. Collectively, this supports the possible utility of SARS-CoV-2 RNAemia as a prognostic marker in COVID-19. With potent antiviral agents in the pipeline, early markers of severe disease will facilitate the identification of patients who may benefit the most from these new therapeutics, particularly as early initiation tends to be a critical factor in antiviral drug efficacy [4].
Our data do not support the use of upper respiratory RT-PCR Ct values as a prognostic tool in COVID-19. This contrasts with two previous reports reporting lower ORF1ab Ct values in patients with severe disease and high mortality [5, 6]. On the other hand, negative upper respiratory PCRs are not uncommon in patients with severe COVID-19 [7], and high RNA loads are frequently detected in individuals with few or no symptoms [8]. Furthermore, differences in sampling techniques and specimen type, PCR targets (ORF1ab vs. E gene), and variations in preanalytical conditions may contribute to discrepant findings.

We found no evidence that viral RNA in plasma or the upper respiratory tract influenced development of SARS-CoV-2-specific antibodies during acute infection. Several retrospective studies have found higher levels of IgG in patients with more severe COVID-19 [9, 10], but other investigators, like us, have detected no such association [11]. Larger prospective studies with long-term follow-up data will be required to determine the significance of SARS-CoV-2-specific antibodies in acute infection and subsequent re-challenge.

This was a single center study, which may limit the generalizability of our findings. While patients were recruited consecutively, we were unable to recruit and sample all patients admitted with COVID-19 in the study period and cannot exclude selection bias. The time between baseline sampling and ICU admission was frequently short, largely due to severe clinical disease at presentation. We expect this to be common, which may limit the useful prognostic time window of a marker such as RNAemia. No correction for multiple comparisons was made, potentially increasing the risk of type I statistical errors, and our findings should be replicated in other cohorts.
While we detected RNAemia in a large proportion of patients, quantitative comparisons were limited by frequent RNA loads below the limit of quantitation. Furthermore, the presence of viral RNA does not necessarily represent replication-competent virus. A recent study failed to culture virus from clinical serum samples positive for SARS-CoV-2 RNA by RT-PCR, but Ct values were consistently high, suggesting low RNA copy numbers [12]. Our data cannot determine whether RNAemia represents direct viral involvement in causing extrapulmonary pathology or is merely spill-over from an intense pulmonary infection. Further investigations into the pathogenesis of extrapulmonary SARS-CoV-2 infection should include viral culture assays and mechanistic studies of viral infection of various tissues and cell types.

In conclusion, we found a high proportion of SARS-CoV-2 RNA in the plasma of patients hospitalized with COVID-19, and a significantly higher frequency and level of plasma RNA in patients who were admitted to the ICU or died. SARS-CoV-2 RNAemia may be a useful prognostic marker in COVID-19. The pathophysiological significance of circulating viral RNA must be ascertained by future studies.
NOTES

Acknowledgements:

We are grateful for invaluable contributions by laboratory technicians Subaitha Navaruban, Ahmed Mekhlif and Elisabeth Lysaker, and study nurse Jannicke Dokken and Amyla Abueg. We also thank Haldor Husbby and the Unit of Data Analysis at Akershus University Hospital, Lørenskog, Norway, for help with clinical data acquisition from the data warehouse at Akershus University Hospital.

Funding:

Dr. Prebensen was supported by a grant from the Institute of Clinical Medicine, Faculty of Medicine, University of Oslo.

Disclosures:

Dr. Myhre has served on advisory boards for Novartis and Novo Nordisk, and has received consulting fees from Novartis, AmGen and Novo Nordisk, and grants from South-Eastern Regional Health Authority Norway. Dr. Omland has served on advisory boards for Abbott Diagnostics, Roche Diagnostics and Bayer and has received research support from Abbott Diagnostics, Novartis, Roche Diagnostics, Singulex and SomaLogic via Akershus University Hospital, and speaker’s or consulting fees from Roche Diagnostics, Siemens Healthineers and CardiNor. All other authors report no relevant disclosures. Dr. Omland reports that Biomarker reagents were provided free of charge by Roche Diagnostics. All other authors have no potential conflicts.
References

1. Puelles VG, Lütgehetmann M, Lindenmeyer MT, et al. Multiorgan and Renal Tropism of SARS-CoV-2. N Engl J Med, 2020; 383: 590-592.

2. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill, 2020; 25(3): 2000045.

3. Hogan CA, Stevens B, Sahoo MK, et al. High frequency of SARS-CoV-2 RNAemia and association with severe disease. medRxiv 2020 [Preprint]. May 1, 2020 [cited 2020 July 25]. Available from: https://doi.org/10.1101/2020.04.26.20080101.

4. Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis, 2013; 207(4): 553-563.

5. Magleby R, Westblade LF, Trzebucki A, et al. (2020) Impact of SARS-CoV-2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients with Coronavirus Disease 2019. Clin Infect Dis [in press].

6. Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ, 2020; 369: m1443.

7. Ai T, Yang Z, Hou H, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology, 2020; 296: E32-E40.

8. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature, 2020; 581(7809): 465-469.
9. Long Q-X, Liu B-Z, Deng H-J, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med, 2020; 26(6): 845-848.

10. Sun B, Feng Y, Mo X, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect, 2020; 9(1): 940-8.

11. To KK-W, Tsang OT-Y, Leung W-S, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis, 2020; 20(5): 565-574.

12. Andersson M, Arancibia - Carcamo CV, Auckland K, et al. SARS-CoV-2 RNA detected in blood samples from patients with COVID-19 is not associated with infectious virus. medRxiv 2020 [Preprint]. June 17, 2020 [cited 2020 July 25]. Available from: https://doi.org/10.1101/2020.05.21.20105486.
Table 1: Patient and assay data, by study primary endpoint.

|                           | Ward (N=88) | ICU/death (N=35) | p-value |
|---------------------------|-------------|------------------|---------|
| **Demographic**           |             |                  |         |
| Age, years                | 57.8 ± 16.3 | 64.3 ± 10.7      | 0.031   |
| Male sex, n (%)           | 47 (53.4)   | 25 (71.4)        | 0.07    |
| Caucasian, n (%)          | 47 (53.4)   | 21 (60.0)        | 0.51    |
| **Comorbidity**           |             |                  |         |
| Body mass index, kg/m²    | 28.2 ± 5.3  | 28.5 ± 6.2       | 0.79    |
| Type-2 diabetes mellitus, n (%) | 11 (12)   | 10 (29)          | 0.033   |
| **Clinical**              |             |                  |         |
| Days of symptoms at admission | 9.2 ± 4.8  | 9.5 ± 4.0        | 0.79    |
| NEWS score at admission   | 4 [2.5, 6.0]| 8 [6.0, 10.0]    | <0.001  |
| **Biochemistry at admission** |         |                  |         |
| CRP, mg/L                 | 55 [27, 110]| 120 [50, 220]    | <0.001  |
| Ferritin, ug/L            | 547 [234, 982]| 1135 [487, 2443]| <0.001  |
| D-dimer, mg/L             | 0.5 [0.3, 0.8]| 0.7 [0.4, 1.1]  | 0.027   |
| LDH, U/L                  | 280 [220, 350]| 390 [290, 520]  | <0.001  |
| **Virological**           |             |                  |         |
| Days from baseline sample to ICU admission | 0 [-1, 3] |                  |         |
| Baseline plasma SARS-CoV-2 RNA |          |                  |         |
| RT-PCR positive, n (%)    | 24 (27)     | 24 (69)          | <0.001  |
|                          | Day 3 plasma SARS-CoV-2 RNA |       | Day 9 plasma SARS-CoV-2 RNA |       |       |
|--------------------------|-----------------------------|-------|-----------------------------|-------|-------|
| RT-PCR positive, n (%)   | 11 (17)                     | 19 (59)| <0.001                      |       |       |
| RT-PCR Ct value*         | 38.3 [39.2, 37.3]           | 35.7 [38.5, 34.5] | 0.037                       |       |       |
| $\log_{10}$ RNA copies/mL* | < 2.7                               | 3.4   |       |       |       |
| Admission upper respiratory SARS-CoV-2 RNA RT-PCR Ct value | 26.1 ± 8.1 | 27.3 ± 6.3 | 0.47 |

**Serological**

**Baseline serum antibodies**

|                          |       |       |
|--------------------------|-------|-------|
| Anti-SARS-CoV-2 NP total Ig, AU/mL | 0.1 [0.1, 2.8] | 0.1 [0.1, 2.8] | 0.38 |
| Anti-SARS-CoV-2 Spike IgG, AU/mL    | 5.6 [0, 19.3] | 5.8 [0, 20.2] | 0.95 |

**Day 3 serum antibodies**

|                          |       |       |
|--------------------------|-------|-------|
| Anti-SARS-CoV-2 NP total Ig, AU/mL | 4.5 [0.2, 16.8] | 1.9 [0.2, 6.54] | 0.36 |
| Anti-SARS-CoV-2 Spike IgG, AU/mL    | 21.2 [5.0, 61.1] | 17.9 [7.2, 75.9] | 0.67 |

**Day 9 serum antibodies**
|                       | Value Range      | Reference Range     | P-value |
|-----------------------|------------------|---------------------|---------|
| Anti-SARS-CoV-2 NP total lg, AU/mL | 19 [6.1, 32.6]   | 14.9 [2.1, 20.1]    | 0.10    |
| Anti-SARS-CoV-2 Spike lgG, AU/mL   | 113 [32.6, 187]  | 127 [30.8, 207]     | 0.82    |

**Table legend:** * Values from plasma samples with detectable RNA. P-values are derived from chi-square tests for binary variables, Mann-Whitney tests for skewed continuous variables and student’s t-tests for continuous normally distributed variables. NEWS: National Early Warning Score CRP: C-reactive protein. LDH: lactate dehydrogenase. Ct: cycle threshold. NP: nucleocapsid protein.